<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448435</url>
  </required_header>
  <id_info>
    <org_study_id>110099</org_study_id>
    <nct_id>NCT00448435</nct_id>
  </id_info>
  <brief_title>Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma</brief_title>
  <official_title>A Study to Compare GW815SF HFA MDI With Concomitant Treatment With Salmeterol Xinafoate DPI Plus Fluticasone Propionate DPI and to Assess Long-term Safety of GW815SF HFA MDI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison
      with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus
      fluticasone propionate DPI 50µg 1 inhalation bid in paediatric patients with asthma.

      To evaluate the safety of long-term treatment of GW815SF HFA MDI 25/50µg 1 inhalation bid in
      paediatric patients with asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods</measure>
    <time_frame>Crossover Period Weeks 1-4, and 7-10</time_frame>
    <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period [Weeks 1-4/Weeks 7-10]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods</measure>
    <time_frame>Crossover Period Weeks 1-4, 7-10</time_frame>
    <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods</measure>
    <time_frame>Crossover Period weeks 1-4, 7-10</time_frame>
    <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods</measure>
    <time_frame>Crossover Period weeks 1-4, 7-10</time_frame>
    <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods</measure>
    <time_frame>Crossover Period Weeks 1-4, 7-10</time_frame>
    <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Symptom-Free Nights &amp; Days</measure>
    <time_frame>Crossover Period Week 1-4, 7-10</time_frame>
    <description>Percentage of subjects with Symptom Free Nights &amp; Days after 4 weeks of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Rescue Medication-Free Nights and Days</measure>
    <time_frame>Crossover Period Weeks 1-4, 7-10</time_frame>
    <description>Percentage of subjects with Rescue Medication Free Nights &amp; Days after 4 weeks of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period</measure>
    <time_frame>Extension Period Weeks 11-30</time_frame>
    <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period</measure>
    <time_frame>Extension Period weeks 11-30</time_frame>
    <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period</measure>
    <time_frame>Extension Period weeks 11-30</time_frame>
    <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period</measure>
    <time_frame>Extension Period weeks 11-30</time_frame>
    <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period</measure>
    <time_frame>Extension Period weeks 11-30</time_frame>
    <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Symptom-Free Nights &amp; Days After 20 Weeks of Treatment</measure>
    <time_frame>Extension Period Weeks 11-30</time_frame>
    <description>Percentage of subjects with Symptom Free Nights &amp; Days after 20 weeks of Treatment (at week 30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Rescue Medication-Free Nights &amp; Days After 20 Weeks of Treatment</measure>
    <time_frame>Extension Period Weeks 11-30</time_frame>
    <description>Percentage of subjects with Rescue Medication Free Nights &amp; Days after 20 weeks of Treatment (at week 30).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>SLM+FP First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SFC First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SFC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW815SF HFA MDI</intervention_name>
    <description>salmeterol and fluticasone propionate combination</description>
    <arm_group_label>SFC</arm_group_label>
    <arm_group_label>SFC First</arm_group_label>
    <arm_group_label>SLM+FP First</arm_group_label>
    <other_name>salmeterol/fluticasone propionate combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol and fluticasone propionate</intervention_name>
    <description>salmeterol + fluticasone propionate</description>
    <arm_group_label>SFC First</arm_group_label>
    <arm_group_label>SLM+FP First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Inclusion Criteria for Entry in Run-in Period

        A pediatric patient already diagnosed as having bronchial asthma who meets all of the
        following criteria is eligible for the study:

          -  Male or female patients aged ≥5 and ≤14 years. Enrolment of a female patient of
             childbearing potential is allowed only if she is tested negative in the pregnancy
             testing at the start of Treatment Period 1 and if she agrees to undergo pregnancy
             testing at the protocol-specified timings and to take contraceptive measures without
             fail.

          -  Written informed consent must be obtained from a legally acceptable representative of
             the subject. Consent of the subject him/herself should also be obtained, wherever
             possible, after giving an explanation in an as easy to understand as possible manner.

          -  An outpatient who has been treated with ICS (FP 100μg/day or equivalent) for at least
             4 weeks prior to Visit 1.

          -  Able to use a peak flow meter in a correct manner in the
             investigator's/subinvestigator's judgment.

          -  Able to use MDI and DPI in a correct manner (with the assistance of his/her caregiver
             as necessary) in the investigator's/subinvestigator's judgment.

        Inclusion Criteria for Entry in Treatment Period 1 A subject will be randomized to one of
        the two treatment groups only if he/she has completed the run-in period and meets all the
        following criteria.

          1. Has a mean of morning PEF measurements in the last 7 days of the run-in period
             (excluding the first day of Treatment Period 1) ≤90% of his/her best PEF measurement .

          2. Was able to perform entry in the asthma diary and PEF measurements in a correct manner
             in the investigator's/subinvestigator's judgment.

          3. Able to use MDI and DPI in a correct manner (with the assistance of his/her caregiver
             as necessary) in the investigator's/subinvestigator's judgment.

        Exclusion criteria:

          -  Exclusion Criteria for Entry in Run-in Period

        A patient who applies any of the following criteria is not eligible for the study:

          -  Admitted to the hospital due to asthma exacerbation within 8 weeks prior to Visit 1.

          -  Used systemic steroid within 4 weeks prior to Visit 1.

          -  Received antibacterials or antivirals for treatment of upper or lower respiratory
             tract infection within 2 weeks prior to Visit 1.

          -  Has a safety problem in participation in the study because of a serious, uncontrolled
             systemic disease including nervous system disorder.

          -  Has or is suspected to have deep-seated mycosis or infection to which no effective
             antibacterial agent is available.

          -  Has or is suspected to have hypersensitivity to the investigational product, rescue
             medication or any ingredients of them.

          -  Is pregnant or lactating, may be pregnant, or plans for pregnancy during the study
             period.

          -  Has received the last dose in another clinical study within 2 months prior to this
             study.

          -  Is not eligible for the study in the investigator's/subinvestigator's judgment.

        Exclusion Criteria for Entry in Treatment Period 1

        Enrolment of a subject completing the run-in period into Treatment Period 1 will not be
        allowed if any of the following applies:

          1. Admitted to the hospital due to asthma exacerbation during the run-in period.

          2. Had upper or lower respiratory tract infection during the 2 weeks just before Visit 2.

          3. Used prohibited drugs during the 2 weeks just before Visit 2.

          4. Is not eligible for the study in the investigator's/subinvestigator's judgment.

        Exclusion Criteria for Entry in Treatment Period 2

        Enrolment of a subject completing the washout period into Treatment Period 2 will not be
        allowed if any of the following applies:

          1. Admitted to the hospital due to asthma exacerbation during the washout period.

          2. Had upper or lower respiratory tract infection during the 2 weeks just before Visit 4.

          3. Used prohibited drugs during the 2 weeks just before Visit 4.

          4. Is not eligible for entry in Treatment Period 2 in the
             investigator's/subinvestigator's judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>260-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>245-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>360-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>360-0812</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>154-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>154-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>158-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>158-0097</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2007</study_first_posted>
  <results_first_submitted>January 19, 2009</results_first_submitted>
  <results_first_submitted_qc>June 25, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2009</results_first_posted>
  <last_update_submitted>June 3, 2010</last_update_submitted>
  <last_update_submitted_qc>June 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Salmeterol</keyword>
  <keyword>Fluticasone propionate</keyword>
  <keyword>Salmeterol/Fluticasone propionate combination</keyword>
  <keyword>Pediatric bronchial asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SFC 50/100 Mcg/Day First</title>
          <description>GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).</description>
        </group>
        <group group_id="P2">
          <title>SLM 50 Mcg + FP 100 Mcg/Day First</title>
          <description>SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period I - 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period - 2 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period II - 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extension Period - 20 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Population</title>
          <description>Randomized Population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian-Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods</title>
        <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period [Weeks 1-4/Weeks 7-10]).</description>
        <time_frame>Crossover Period Weeks 1-4, and 7-10</time_frame>
        <population>PPS (Per Protocol Set): randomized subjects less those who did not complete treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
          <group group_id="O2">
            <title>SLM 50 Mcg + FP 100 Mcg/Day</title>
            <description>Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods</title>
          <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period [Weeks 1-4/Weeks 7-10]).</description>
          <population>PPS (Per Protocol Set): randomized subjects less those who did not complete treatment.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="4.53"/>
                    <measurement group_id="O2" value="17.1" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between treatments [(SLM + FP)- SFC](SE) 2.8 (5.91)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin + or - 15 L/min</non_inferiority_desc>
            <p_value>0.6383</p_value>
            <p_value_desc>Confidence Interval</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.10</ci_lower_limit>
            <ci_upper_limit>14.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods</title>
        <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
        <time_frame>Crossover Period Weeks 1-4, 7-10</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
          <group group_id="O2">
            <title>SLM 50 Mcg + FP 100 Mcg/Day</title>
            <description>Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods</title>
          <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
          <population>PPS</population>
          <units>Percentage of predicted value</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="1.543"/>
                    <measurement group_id="O2" value="6.73" spread="1.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods</title>
        <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
        <time_frame>Crossover Period weeks 1-4, 7-10</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
          <group group_id="O2">
            <title>SLM 50mcg + FP 100 Mcg/Day</title>
            <description>Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods</title>
          <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
          <population>PPS</population>
          <units>Percentage of personal best value</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="1.480"/>
                    <measurement group_id="O2" value="6.46" spread="1.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods</title>
        <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
        <time_frame>Crossover Period weeks 1-4, 7-10</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
          <group group_id="O2">
            <title>SLM 50 Mcg + FP 100 Mcg/Day</title>
            <description>Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods</title>
          <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
          <population>PPS</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="3.74"/>
                    <measurement group_id="O2" value="15.8" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods</title>
        <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
        <time_frame>Crossover Period Weeks 1-4, 7-10</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
          <group group_id="O2">
            <title>SLM 50 Mcg + FP 100 Mcg/Day</title>
            <description>Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods</title>
          <description>Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.</description>
          <population>PPS</population>
          <units>Percentage of circadian variation</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.638"/>
                    <measurement group_id="O2" value="-0.08" spread="0.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Symptom-Free Nights &amp; Days</title>
        <description>Percentage of subjects with Symptom Free Nights &amp; Days after 4 weeks of Treatment</description>
        <time_frame>Crossover Period Week 1-4, 7-10</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
          <group group_id="O2">
            <title>SLM 50 Mcg + FP 100 Mcg/Day</title>
            <description>Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Symptom-Free Nights &amp; Days</title>
          <description>Percentage of subjects with Symptom Free Nights &amp; Days after 4 weeks of Treatment</description>
          <population>PPS</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9"/>
                    <measurement group_id="O2" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 4 Weeks of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Rescue Medication-Free Nights and Days</title>
        <description>Percentage of subjects with Rescue Medication Free Nights &amp; Days after 4 weeks of Treatment</description>
        <time_frame>Crossover Period Weeks 1-4, 7-10</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
          <group group_id="O2">
            <title>SLM 50 Mcg + FP 100 Mcg/Day</title>
            <description>Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Rescue Medication-Free Nights and Days</title>
          <description>Percentage of subjects with Rescue Medication Free Nights &amp; Days after 4 weeks of Treatment</description>
          <population>PPS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 4 Weeks of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period</title>
        <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).</description>
        <time_frame>Extension Period Weeks 11-30</time_frame>
        <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period</title>
          <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).</description>
          <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="24.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period</title>
        <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
        <time_frame>Extension Period weeks 11-30</time_frame>
        <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period</title>
          <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
          <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
          <units>Percentage of predicted value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="9.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period</title>
        <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
        <time_frame>Extension Period weeks 11-30</time_frame>
        <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period</title>
          <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
          <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
          <units>Percentage of personal best value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="8.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period</title>
        <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
        <time_frame>Extension Period weeks 11-30</time_frame>
        <population>FAS (Full Analysis Set) during the Exension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period</title>
          <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
          <population>FAS (Full Analysis Set) during the Exension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
          <units>L/Min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="23.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period</title>
        <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
        <time_frame>Extension Period weeks 11-30</time_frame>
        <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period</title>
          <description>Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).</description>
          <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
          <units>Percentage of circadian variation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="3.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Symptom-Free Nights &amp; Days After 20 Weeks of Treatment</title>
        <description>Percentage of subjects with Symptom Free Nights &amp; Days after 20 weeks of Treatment (at week 30).</description>
        <time_frame>Extension Period Weeks 11-30</time_frame>
        <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Symptom-Free Nights &amp; Days After 20 Weeks of Treatment</title>
          <description>Percentage of subjects with Symptom Free Nights &amp; Days after 20 weeks of Treatment (at week 30).</description>
          <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 20 weeks of treatment (at week 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Rescue Medication-Free Nights &amp; Days After 20 Weeks of Treatment</title>
        <description>Percentage of subjects with Rescue Medication Free Nights &amp; Days after 20 weeks of Treatment (at week 30).</description>
        <time_frame>Extension Period Weeks 11-30</time_frame>
        <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
        <group_list>
          <group group_id="O1">
            <title>SFC 50/100 Mcg/Day</title>
            <description>Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Rescue Medication-Free Nights &amp; Days After 20 Weeks of Treatment</title>
          <description>Percentage of subjects with Rescue Medication Free Nights &amp; Days after 20 weeks of Treatment (at week 30).</description>
          <population>FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 20 weeks of treatment (at week 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SFC 50/100 Mcg/Day</title>
          <description>Safety Population who received GW815SF (SFC, Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in Crossover Period Weeks 1-4 and 7-10</description>
        </group>
        <group group_id="E2">
          <title>SLM 50 + FP 100 Mcg/Day</title>
          <description>Safety Population who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily in Crossover Period Weeks 1-4 and 7-10</description>
        </group>
        <group group_id="E3">
          <title>SFC 50/100mcg/Day (Extension Period)</title>
          <description>Safety Population who switched to Extension Period and received GW815SF HFA MDI 25/50mcg twice daily during the Extension period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit an investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not preceed the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

